PMGC Holdings Stock Price, News & Analysis

Elevai Labs announced that its CEO, Dr. Jordan R. Plews, will present at the 2024 Beauty Through Science (BTS) conference in Stockholm on May 30, 2024. BTS is a prestigious annual event attracting over 1,000 participants from around 50 countries, focusing on innovative techniques and technologies in aesthetic medicine. Dr. Plews will discuss the role of exosomes in medical aesthetics during a session titled 'Exosomes: Key Considerations, Regulations and Results,' emphasizing their benefits in promoting natural repair processes. Elevai's participation underscores its commitment to advancing science-driven, data-backed skincare solutions.

Elevai Labs, a leader in medical aesthetics, announced that CEO Dr. Jordan R. Plews will present at the LA-BEST 2024 conference on May 23, 2024. This event, organized by UCLA Technology Development Group, brings together around 1,000 participants to foster biotech innovation. Dr. Plews will discuss Elevai Biosciences' engineered probiotic approach for muscle loss prevention in obesity, particularly focusing on combining this approach with GLP-1 receptor agonists. He will highlight their lead candidate, EL-22, which aims to preserve muscle mass through mucosal immunity and anti-myostatin antibodies. The conference aims to promote biotech partnerships and showcase pioneering research.

Elevai Labs (NASDAQ: ELAB) reported financial results for Q1 2024, showcasing substantial year-over-year revenue growth and improved gross margins. The company achieved $614,563 in revenue, up 330.3% from $142,820 in Q1 2023, but down 12% from Q4 2023. Gross margin rose to 72.5%, compared to 68.9% in Q1 2023. However, operating expenses increased to $2,129,113, a 125.4% year-over-year rise and a 38% increase from Q4 2023, leading to a total comprehensive loss of $1,396,069. Elevai Labs remains focused on sustainable growth, operational efficiency, and innovation.

Elevai Biosciences highlighted preclinical data on their in-licensed asset EL-22 for potential obesity treatment. The data showed improvements in muscle mass and fat reduction in mouse models of Duchenne muscular dystrophy. Elevai plans to submit an IND application in 2025 for clinical trials combining EL-22 with GLP-1 receptor agonists.

Elevai Labs, Inc. announced the establishment of two new subsidiaries - Elevai Biosciences, Inc., and Elevai Skincare, Inc. Elevai Biosciences will focus on developing biopharmaceutical technologies with lead assets targeting indications related to obesity. Elevai Skincare will commercialize exosome skincare technologies for the medical skincare market. The restructuring aims to enhance focus, agility, and market penetration for accelerated growth and profitability.

Elevai Labs has acquired exclusive rights to two myostatin muscle loss prevention assets, EL-22 and EL-32, for the treatment of obesity. EL-22 has shown promising results in preclinical trials, increasing body weight and restoring muscle damage. The company aims to combine these assets with popular GLP-1 obesity treatments to improve the standard of care for obesity patients. Elevai plans to submit an IND application in 2025 for further clinical trials in the U.S. market. The CDC reports that 42% of adults suffer from obesity, creating a large market opportunity for weight-loss medications.

The licensing agreement with MOA Life Plus Co., includes global rights excluding South Korea. The agreement involves upfront cash, equity considerations, milestone payments, and royalties based on development and sales milestones. Elevai's approach to muscle preservation while decreasing fat mass could address the current challenge of muscle loss associated with GLP-1 weight-loss drugs, offering a unique solution to the obesity epidemic.

ELEVAI Labs Inc. (NASDAQ: ELAB), a medical aesthetic company, highlights global distribution agreements securing up to $4.9M in revenue commitments over five years. With five agreements signed and five more in discussion, Elevai aims to expand its global presence with innovative skincare solutions tailored to diverse markets. The company's distribution partners will lead marketing efforts, ensuring seamless product entry and compliance in various regions.